Table 1c. The relationship between the mGPS, biochemical parameters and survival in patients sampled within 2 years before cancer diagnosis in the Glasgow Inflammation Outcome Study.
|
Overall survival
|
Cancer-specific survival
|
|||
|---|---|---|---|---|
| HR | P-value | HR | P-value | |
| mGPS | ||||
| 0 | 1 | <0.001 | 1 | <0.001 |
| 1 | 1.79 | <0.001 | 1.92 | <0.001 |
| 2 | 2.87 | <0.001 | 3.01 | <0.001 |
| Adjusted calcium | ||||
| <2.10 mmol l−1 | 1.25 | 0.001 | 1.15 | 0.070 |
| 2.10–2.60 mmol l−1 | 1 | <0.001 | 1 | <0.001 |
| >2.60 mmol l−1 | 2.30 | <0.001 | 2.38 | <0.001 |
| Bilirubin | ||||
| <20 μmol l−1 | 1 | <0.001 | 1 | <0.001 |
| ⩾20 μmol l−1 | 1.53 | <0.001 | 1.55 | <0.001 |
| Alkaline phosphatase | ||||
| <80 U l−1 | 0.71 | 0.012 | 0.74 | 0.037 |
| 80–280 U l−1 | 1 | <0.001 | 1 | <0.001 |
| >280 U l−1 | 2.12 | <0.001 | 2.19 | <0.001 |
| Aspartate transaminase | ||||
| <40 U l−1 | 1 | <0.001 | 1 | <0.001 |
| ⩾40 U l−1 | 1.66 | <0.001 | 1.73 | <0.001 |
| Alanine transaminase | ||||
| <50 U l−1 | 1 | <0.001 | 1 | <0.001 |
| ⩾50U l−1 | 1.36 | <0.001 | 1.39 | <0.001 |
| γ-Glutamyl transferase | ||||
| M<70 U l−1; F<40 U l−1 | 1 | <0.001 | 1 | <0.001 |
| M⩾70 U l−1; F⩾40 U l−1 | 1.85 | <0.001 | 1.85 | <0.001 |
Abbreviations: HR=hazard ratio; mGPS=modified Glasgow Prognostic Score.
Adjusted for age, sex, deprivation and stratified by tumour site.